Press Releases

Theoretical physicists from Berlin teamed up with experimental physicists from Munich to determine the precise mechanics involved in cell motility. The findings were published in the journal Proceedings of the National Academy of Sciences (PNAS).

MDC researchers have developed a new approach to CAR T-cell therapy. The team has shown in Nature Communications that the procedure is very effective, especially when it comes to fighting follicular lymphomas and chronic lymphocytic leukemia, the most common type of blood cancer in adults.

On January 1, 2021, the Berlin Institute of Health (BIH ) will become the translational research unit of Charité – Universitätsmedizin Berlin and will then form – alongside the hospital and the medical faculty – Charité’s third pillar.

Colon cancer stem cells have one weak spot: the enzyme Mll1. An MDC team led by Walter Birchmeier has now shown in Nature Communications that blocking this protein prevents the development of new tumors in the body.

The European Research Council (ERC) awarded Dr. Mina Gouti a €2.8 million Consolidator Grant to further develop miniature neuromuscular organoids for studying neuromuscular development and diseases. It was the second honor in as many weeks; she was also named an EMBO Young Investigator for her work.

A large grant under the NIH’s 4D Nucleome Program supports MDC scientist Ana Pombo’s work as a member of a multi-team consortium led by UC San Diego in the U.S. The team will investigate how DNA organizes inside cell nuclei and functions in space and time.

A new algorithmic approach reveals individual tumors continue to evolve and remodel their genomes, and this occurs across a broad range of tumor types. Identifying changes that benefit tumors and help them metastasize could help with future treatments. Results are published in Nature.

MDC researchers received a $150,000 pilot project grant from the Chan Zuckerberg Initiative’s Neurodegeneration Challenge Network to investigate a defining feature of amyotrophic lateral sclerosis (ALS).

The Berlin biotech start-up T-knife, a spin-off from the MDC together with Charité, has secured investments totaling €66 million. Four venture capital funds committed to the financing in early August. T-knife develops new cancer treatments using modified immune system T cells.

A severe course of COVID-19 does not solely result in a strong immune reaction – rather, the immune response is caught in a continuous loop of activation and inhibition. This is reported in Cell by experts of the nationwide deCOI research network, including colleagues at the MDC.